 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...2829303132333435363738...235236» |
- Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center. (Level 1, West Hall; Poster Bd # D2) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_686;
pCR rates appear lower than reported studies. Understanding the limitation of retrospective studies, further analysis is ongoing to determine if factors other than sequence of modality can contribute to the observed findings.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors. (Level 1, West Hall; Poster Bd # C18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_684;
This suggests that unlike sporadic CRC, CAC may not be driven primarily by EGFR. Many had high grade histology and unusual sites of metastases (bone, soft tissue).
- Patterns of presentation and delivery of care of appendiceal neoplasms in the largest municipal health care delivery system in the United States. (Level 1, West Hall; Poster Bd # B15) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_661;
50% of AN presented as appendicitis emphasizing the need for a robust system to identify these cases. Despite challenges encountered in providing long-term oncological care, HHC has treated and provided vigorous follow-up for this underserved population.
- Jemperli (dostarlimab-gxly) / GSK
AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer. (Level 1, West Hall; Poster Bd # P8) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_653;
P3
Editorial support provided by Fishawack Health, funded by GSK. Clinical trial information: NCT05855200.
- 5-fluorouracil / Generic mfg.
No operation after short course radiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer: The prospective, single arm NOAHS-ARC trial. (Level 1, West Hall; Poster Bd # P5) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_650;
P2
power of 80% and error of 10% will be 73 patients. Clinical trial information: NCT04864067.
- MK-1084 / Merck (MSD), Otsuka
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors. (Level 1, West Hall; Poster Bd # N20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_645;
P1
Clinical trial information: NCT04864067. ESMO 2023; Abs 3156) indicated antitumor activity in pts with solid tumors receiving oral MK-1084 monotherapy QD or BID (25 to 800 mg total daily; arm 1) and pts with previously untreated non
- Tecentriq (atezolizumab) / Roche
Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) (Level 1, West Hall; Poster Bd # N19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_644;
P3
Upon AtezoTRIBE subgroup analysis of the 8 pts with dMMR mCRC treated with FOLFOXIRI+bev+atezo, median PFS was not reached, with the first patient having progression ~16 mos...Support: U10CA180868, -180822, -180888, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT02997228.
- irinotecan / Generic mfg.
mFOLFIRINOX versus mFOLFOX 6 as adjuvant treatment for high-risk stage III colon cancer (FROST trial): Study protocol for an open label, multicenter, randomized, phase II study. (Level 1, West Hall; Poster Bd # N18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_643;
P2/3
Clinical trial information: NCT02997228. Given the proven efficacy of triplet chemotherapy in metastatic colorectal cancer, this study aims to assess the effectiveness and toxicity of modified 5-fluoropyrimidine (5-FU)/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) in comparison with the current standard of care
- KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT. (Poster Bd # N18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_623;
Median duration of NST was 9 cycles, and common agents included Gemcitabine and Abraxane (21%); FOLFIRINOX (28%); a combination of the two regimens (41%); or other NSTs (10%)... For localized PDAC pts inoperable at diagnosis who received NST followed by MRgSBRT, KRAS was the only significant predictor of ORR and OS, highlighting the need for further treatment intensification in KRAS-mt pts.
- The impact of Wnt pathway alterations including RNF43, GNAS, CTNNB1, and APC on prognosis and potential therapeutic vulnerability in pancreatic adenocarcinoma (PDAC). (Poster Bd # N7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_612;
The presence of Wnt pathway alterations identifies a subgroup of advanced PDAC with improved PFS and OS. >
- Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma. (Poster Bd # N3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_608;
Potential predictive associations favoring FFX over GA in the TP53 LOF subgroup (but not in GOF or WT subgroups) warrant further exploration. >
- 5-fluorouracil / Generic mfg.
Mucin 5 AC (MUC5AC) to predict pathologic treatment response (TR) to neoadjuvant chemotherapy (NAT) in resected-pancreatic ductal adenocarcinoma (R-PDA). (Poster Bd # M19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_604;
These associations must be validated in further prospective studies. >
- Clinical outcomes and molecular characteristics of patients with pancreatic acinar cell carcinoma. (Poster Bd # M17) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_602;
In addition, more than one-third of the pts harbored germline mutations in HR genes. Therefore, somatic and germline testing should be considered for any pt diagnosed with PACC.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Kinetics of CA19-9 decline in a randomized phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracial/leucovorin (NALIRIFOX) or nab-paclitaxel plus gemcitabine (GEM+NABP) in patients who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (NAPOLI 3). (Poster Bd # M16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_601;
P3
The results should be interpreted with caution as a considerable percentage of patients were excluded due to non-evaluable CA19-9 that exceeded the lab detection limit of 8000 kU/L. Clinical trial information: NCT04083235.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Lymphopenia and spleen dose for patients with inoperable pancreatic cancer receiving ablative 5-fraction radiation therapy. (Poster Bd # M15) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_600;
We observed a similar incidence of grade 2+ lymphopenia compared to prior 5-fraction NA-RT studies. There was a trend towards significance of higher spleen V5Gy being associated with a higher probability of G3L.
- albumin-bound paclitaxel / Generic mfg.
Molecular characterization of small extracellular vesicles in patients with pancreatic cancer treated with neoadjuvant chemotherapy followed by stereotactic body radiation (SBRT). (Poster Bd # M14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_599;
P1
Neoadjuvant chemotherapy in combination with SBRT is safe and tolerable regimen to treat patients with locally advanced and borderline PanC. Further, sEV in the plasma of PanC patients could serve as useful prognostic and predictive markers.
- Imfinzi (durvalumab) / AstraZeneca, Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study. (Poster Bd # M2) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_588;
P2
Data on genomic alterations analyses will be presented at the congress. Clinical trial information: NCT04348045.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
FOLFIRINOX plus high intensity focused ultrasound for locally advanced/borderline resectable pancreatic ductal adenocarcinoma: A prospective single arm phase II trial. (Poster Bd # L19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_585;
P=N/A
FOLFIRINOX plus HIFU was safe and effective treatment for LAPC/BRPC, providing 60.0% of partial response rate without any additional AE to chemotherapy. Clinical trial information: NCT05262452.
- PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. (Poster Bd # L18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_584;
Further work is ongoing to identify potential biomarkers which may lead to better patient selection for a neoadjuvant approach. Clinical trial information: ISRCTN34129115.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Postoperative complications following neoadjuvant therapy and surgery in a phase 2 borderline resectable pancreatic cancer clinical trial (Alliance A021501). (Poster Bd # L13) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_579;
P2
Multimodality trials of preoperative therapy for locoregionally advanced pancreatic cancer may be safely performed in the cooperative group setting. Clinical trial information: NCT02839343.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Phase II study of the safety and efficacy of discontinuing pegfilgrastim for pancreatic adenocarcinoma treated with FOLFIRINOX. (Poster Bd # L12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_578;
FOLFIRINOX can be continued safely with a low incidence of FN after discontinuing pegfilgrastim in PDAC patients who did not experience FN during the first three courses of FOLFIRINOX, if the drug dose is reduced appropriately for neutropenia from the fourth course. Clinical trial information: UMIN000028055.
- 5-fluorouracil / Generic mfg.
Non-responders to neoadjuvant chemotherapy in pancreatic adenocarcinoma: Characteristics and outcomes. (Poster Bd # L11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_577;
Chemotherapy switch was employed mostly in cases with worse prognostic factors and thus infrequently lead to resection. Despite this, patients who underwent CS had similar overall survival to those who did not.
- Onivyde (nanoliposomal irinotecan) / Servier, Ipsen, Takeda
Results of a phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study). (Poster Bd # L4) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_571;
P2
Additional analyses are ongoing and will be reported at the meeting. Clinical trial information: NCT03483038.
- 5-fluorouracil / Generic mfg.
Safety and efficacy of chemotherapy for patients with unresectable pancreatic cancer concomitant with collagen disease: A multicenter retrospective observational study. (Poster Bd # K19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_566;
The most common regimens for pancreatic cancer were gemcitabine/nab-paclitaxel (GnP, n=40), S-1 monotherapy (n=18), gemcitabine monotherapy (n=15), modified FOLFIRINOX (n=10), S-1 concurrent radiotherapy (n=5), and FOLFOX (n=4)... Patients with pancreatic cancer concomitant with collagen disease have a high discontinuation rate due to AEs, and attention should be given to the occurrence of thrombosis and ILD.
- Opdivo (nivolumab) / Ono Pharma, BMS
Stereotactic radiotherapy plus anti PD-1 therapy in patients with locally advanced unresectable pancreatic cancer: Results from a phase 1/2 clinical trial (CA209-9KH). (Poster Bd # K18) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_565;
P1/2
There was no unexpected toxicity of combination of SRT of PDAC primary tumor and N, but this regimen did not lead to any long-term treatment responses. Trial registration: EudraCT: 2017-003404-52; ClinicalTrials.gov: NCT04098432.
- Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first line treatment. (Poster Bd # K16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_563;
This new triplet regimen could be a useful first line treatment option for patients with metastatic pancreatic cancer. Clinical trial information: jRCTs011190008.
- Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Associations between BMI, morphomics and survival in 528 patients with metastatic pancreatic cancer. (Poster Bd # K6) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_553;
BMI was not associated with PFS or OS in this large prospective study of patients with metastatic PDA receiving chemotherapy. However, morphomic variables including subcutaneous fat area, visceral fat density, and the muscle to fascia ratio were statistically significantly associated with metastatic PDA patient survival.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy? (Poster Bd # J17) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_546;
A RW cohort of mPDAC pts receiving FFX-only experienced more AEs per pt-month of 1L and reduced likelihood of proceeding to subsequent lines of therapy compared to pts treated with FFX + GnP. Identifying predictive biomarkers may distinguish FFX non-responders and obviate AEs.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line. (Poster Bd # J16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_545;
Identifying predictive biomarkers may distinguish FFX non-responders and obviate AEs. In a RW sample of 2,212 pts receiving 1L FFX and mFFX at primarily community oncology practices in the United States from 2014
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
De-escalation and dose density in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line. (Poster Bd # J15) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_544;
De-escalation was common among pts continuing FFX/mFFX treatment, with oxaliplatin the most frequently omitted component in later administrations. Over the 6 weeks following FFX treatment initiation, the actual vs. standard dose was lowest for 5FU, followed by irinotecan, while median leucovorin and oxaliplatin doses were close to standard dose over 3 two-week cycles.
- Nutritional impact and prognostic role of systemic inflammatory response index (SIRI) in advanced pancreatic cancer: PANTHEIA-Spanish Society of Medical Oncology (SEOM) study results. (Poster Bd # J10) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_539;
Our findings underscore the importance of SIRI as a significant predictor of nutritional status and disease aggressiveness in patients with metastatic pancreatic cancer. Prospective data will help us to validate these findings.
- Clinical impact of KRAS mutations in metastatic pancreatic ductal adenocarcinoma (PDAC). (Poster Bd # J6) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_535;
KRAS G12C was associated with the shortest OS among common KRAS mutations. >
- 5-fluorouracil / Generic mfg.
Association of race and CA 19-9 nonproduction with limited pathologic response to neoadjuvant chemotherapy in patients with localized pancreatic cancer. (Poster Bd # H15) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_525;
CAnonprod were more likely to be Black and have significantly worse rates of MPR following neoadjuvant chemotherapy in patients with localized PDAC. Moreover, CAnonprod was associated with higher rates of SWI/SNF alterations, noting a potential biologic basis for racial differences in chemotherapy response to curative-intent treatment for PDAC.
- 5-fluorouracil / Generic mfg.
Second-line chemotherapy in elderly patients with advanced pancreatic cancer: A mono-institutional retrospective experience. (Poster Bd # H12) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_522;
The regimens of chemotherapy used were: mFOLFOX (28; 46%), Gemcitabine (11; 18%), Capecitabine (15; 24.6%), FOLFIRI (6; 9.8%), mFOLFIRINOX (1; 1.6%)... In our experience, only about a third of elderly pts with APC received second-line therapy; in these patients, ECOG PS, disease
- Tevimbra (tislelizumab) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study. (Poster Bd # D7) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_443;
The study is ongoing, OS will be reported later. Clinical trial information: ChiCTR2200064384.
- Characterization of outcomes and genomic alterations (GA) in combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). (Poster Bd # B3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_402;
Pts who present with early stage of disease should be evaluated early for surgical resection or maximize local therapy in the case of nonresectable disease to improve survival. >
- Tibsovo (ivosidenib) / Servier
Real-world testing, treatment patterns, and outcomes following liquid biopsy in advanced cholangiocarcinoma. (Poster Bd # A20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_399;
Patients with aCCA are often tested before starting first or second LOT. Patients with ctDNA-detected IDH1 mutations treated with ivosidenib and had a trend toward improved rwTTD and rwTTNT, although it did not reach statistical significance.
- BMF-219 / Biomea Fusion
COVALENT-102: A phase 1/1b dose finding study of BMF-219, an oral covalent menin inhibitor, in adults with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC), pancreatic cancer (PDAC) and colorectal cancer (CRC) with activating KRAS mutations. (Poster Bd # Q5) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_374;
P1
Patients with ctDNA-detected IDH1 mutations treated with ivosidenib and had a trend toward improved rwTTD and rwTTNT, although it did not reach statistical significance. Eligible patients include those with any KRAS mutation and (Cohort 1) stage IIIB/IV NSCLC with 2-4 prior lines of therapy including immune checkpoint inhibitors (ICI) &/or platinum-based chemo
- albumin-bound paclitaxel / Generic mfg.
DIsCOvER: A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial to investigate the efficacy and safety of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in patients with locally advanced or metastatic pancreas cancer during first-line chemotherapy. (Poster Bd # P20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_369;
P3
Locally advanced or metastatic pancreas cancer pts from Austria and Germany with age of ?18 yrs tolerating FOLFIRINOX or gemcitabine/nab-paclitaxel based ctx are eligible for enrolment...The DIsCOvER trial is the first randomized, placebo-controlled phase III trial that investigates the impact of individually dosed dronabinol in cancer pts (Registration: NCT03984214). Clinical trial information: NCT03984214.
- PDS01ADC / PDS Biotech
Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma. (Poster Bd # P15) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_364;
P2
To date, we have enrolled 8 of 23 patients in Cohort 1. Clinical trial information: NCT05286814.
- Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma. (Poster Bd # P8) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_357;
Secondary endpoints are median PFS and overall survival (OS), disease control rate (DCR) per RECIST 1.1, quality of life (QOL) and safety. Recruitment for this study will complete in December 2024.
- tinengotinib (TT-00420) / TransThera Biosci
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor (Poster Bd # P4) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_353;
P1, P1/2,
The first generation FGFR inhibitors (FGFRi) pemigatinib and futibatinib, have been approved for the treatment of advanced CCA with FGFR2 fusions or rearrangements after systemic chemotherapy...The study includes Part A and Part B. The Part A is to select a dose for Part B. Eligible subjects will be randomized in a 2:2:1 ratio to receive tinengotinib 8 mg QD, tinengotinib 10 mg QD or Physician's Choice (FOLFOX or FOLFIRI) in Part A or 2:1 in Part B to receive the recommended Part B dose or Physician's Choice...Study is open for enrollment. Clinical trial information: NCT05948475.
- Keytruda (pembrolizumab) / Merck (MSD)
Pembrolizumab plus FLOT vs FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: Interim analysis of the phase 3 KEYNOTE-585 study. () - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_340;
P3
PathCR and EFS favored pembro + FLOT vs pbo + FLOT in pts with untreated, locally advanced resectable G/GEJ cancer. Clinical trial information: NCT03221426.
- Imfinzi (durvalumab) / AstraZeneca
Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. () - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_339;
P3
The study is ongoing for the primary objective of event-free survival. Clinical trial information: NCT04592913.
- Avastin (bevacizumab) / Roche
Phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with gastrointestinal (GI) cancers receiving FOLFOX chemotherapy with or without bevacizumab. (Poster Bd # L20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_318;
P1
140mg was the chosen RP2D. A randomized phase II study is planned using D to prevent OPIN.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
PD1 and CD39 expression on tumor infiltrating lymphocytes in patients with gastric cancer. (Poster Bd # H19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_260;
A randomized phase II study is planned using D to prevent OPIN. DP-TILs may have superior T cell receptors recognizing tumor-antigens and contribute to tumor eradication, especially when administrated anti-CD39 antibody.
- zolbetuximab (IMAB362) / Astellas
Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2?, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies. (Poster Bd # H14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_255;
P3
These strategies will be important to support continued treatment and allow pts to achieve maximum clinical benefit with zolbetuximab + chemotherapy. Clinical trial information: NCT03504397 and NCT03653507.
- FLOT compared to FOLFOX/XELOX as a neoadjuvant chemotherapy in locally advanced gastric cancer: Experience of two clinics. (Poster Bd # H3) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_244;
We report that triplet regimen (FLOT) in comparison with doublet (FOLFOX/XELOX) regimen is the more favorable option as a neoadjuvant setting in locally advanced gastric cancer. FLOT NCT is associated with increased ypN0, pCR and shows statistically significant difference in PFS and OS.
- Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial of the AIO/CAOGI/ACO. (Poster Bd # G20) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_242;
P3
A negative diagnostic laparoscopy before treatment and 3-6 pre-operative cycles of FLOT are a prerequisite for enrollment (Docetaxel 50 mg/m2; Oxaliplatin 85 mg/m2; Leucovorin 200 mg/m2; 5-FU 2600 mg/m2, q2wk). Pts were randomized 1:1 to receive surgery only and postoperative FLOT (Arm A-control arm) or surgery + intraoperative HIPEC (cisplatin 75mg/m2 solution at 42
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma. (Poster Bd # G16) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_239;
P1/2
Pathologic response data are promising. Accrual is ongoing and updated data will be presented.